HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Commission Seeks Cosmetic Nanotech Experts For Committee Work

This article was originally published in The Rose Sheet

Executive Summary

With European nanotechnology regs going into effect in January 2013 for manufacturers of cosmetic products, the European Commission expects its Scientific Committee on Consumer Safety to be busy reviewing nanomaterials that come to the commission’s attention. To ensure that SCCS is well-informed, the EC has issued a call for nanotech experts.

You may also be interested in...



U.S., EU Nanotech Guidances Demonstrate “Growing Consensus” – PCPC

The Personal Care Products Council’s Jay Ansell, VP of cosmetic programs, is optimistic about the direction regulators are taking and the consensus developing among scientific experts regarding the use of nanomaterials in cosmetics. However, challenges remain for firms faced with requirements under European law, and further harmonization is needed between international regulatory regimes, he suggests.

In Brief

European Commission’s Scientific Committee on Consumer Safety releases guidance to help firms comply with nanotech reporting and labelling requirements that go into effect next year under the recast European Cosmetics Directive. More news in brief.

Clinical Studies May Be Needed For Cosmetics With Nanomaterials – FDA

Due to nanomaterials’ size and the unique behavior they often exhibit, standard tests – and particularly in vitro tests – for assessing product safety may not be appropriate for use, FDA says in new guidance to the cosmetics industry. The agency encourages firms to consult with its cosmetics office prior to launching nanotech-containing products to market.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel